During the last session, Ekso Bionics Holdings Inc (NASDAQ:EKSO)’s traded shares were 0.33 million, with the beta value of the company hitting 1.32. At the end of the trading day, the stock’s price was $0.39, reflecting an intraday loss of -4.17% or -$0.01. The 52-week high for the EKSO share is $1.64, that puts it down -320.51 from that peak though still a striking 5.13% gain since the share price plummeted to a 52-week low of $0.37. The company’s market capitalization is $9.58M, and the average trade volume was 1.18 million shares over the past three months.
Ekso Bionics Holdings Inc (EKSO) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. EKSO has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Ekso Bionics Holdings Inc (NASDAQ:EKSO) trade information
Ekso Bionics Holdings Inc (EKSO) registered a -4.17% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -4.17% in intraday trading to $0.39, hitting a weekly high. The stock’s 5-day price performance is -26.43%, and it has moved by -29.74% in 30 days. Based on these gigs, the overall price performance for the year is -75.56%.
The consensus price target of analysts on Wall Street is $2, which implies an increase of 80.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, EKSO is trading at a discount of -412.82% off the target high and -412.82% off the low.
Ekso Bionics Holdings Inc (EKSO) estimates and forecasts
In the rating firms’ projections, revenue will increase 22.71% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 4.62M as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 5.51M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 3.76M and 4.95M respectively. In this case, analysts expect current quarter sales to grow by 23.12% and then jump by 11.30% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 25.99%. While earnings are projected to return 42.86% in 2025.
EKSO Dividends
Ekso Bionics Holdings Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 0.59 million shares, is of VANGUARD GROUP INC’s that is approximately 3.4125% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.63 million.
Also, the Mutual Funds coming in first place with the largest holdings of Ekso Bionics Holdings Inc (EKSO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 400.89 shares. This amounts to just over 1.61 percent of the company’s overall shares, with a $0.15 million market value. The same data shows that the other fund manager holds slightly less at 179.46, or about 0.72% of the stock, which is worth about $69287.0.
